Latest Regulatory Milestones News

Percheron Therapeutics reports encouraging phase I clinical results for HMBD-002, confirming safety and early efficacy signals, while gearing up for a multi-arm phase II trial in 2026.

Globe Metals & Mining advances its Kanyika Niobium Project with a regulatory extension, licence expansion to new critical minerals, and a significant capital raise, positioning the company for its next development phase.

Cobre Limited has reported a maiden Mineral Resource Estimate for its Ngami Copper Project in Botswana, alongside a significant investment agreement with Sinomine International Exploration. The company also advanced exploration activities with BHP funding and progressed key permitting milestones.

Far East Gold reports a productive September quarter with significant drilling results at its Idenburg Project, including a new high-grade discovery at North Bermol and an expanded pipeline of exploration targets.

Piche Resources has secured crucial environmental approvals for its Argentine projects, setting the stage for an extensive drilling campaign at Cerro Chacón and advancing uranium exploration at Sierra Cuadrada and Ashburton.

Legacy Iron Ore Limited reported solid progress in its September 2025 quarter, advancing gold production at South Laverton and pushing forward feasibility and environmental studies at the Mount Bevan magnetite project.

Cobalt Blue Holdings advances its Kwinana Cobalt Refinery with a critical Works Approval and secures letters of intent covering 70% of initial production, while its Broken Hill Cobalt Project gains a three-year Major Project Status extension.

Southern Palladium has cleared major regulatory hurdles and confirmed robust economics for its Bengwenyama platinum group metals project, supported by a $20 million capital raise to fund next-stage development.

Cleo Diagnostics has successfully completed Stage 1 of the Medical Device Single Audit Program, marking a significant step toward FDA submission and global commercialisation of its ovarian cancer test.

Paradigm Biopharmaceuticals has initiated dosing in its pivotal Phase 3 trial for knee osteoarthritis pain, backed by a strong cash position and strategic portfolio expansion. The company targets accelerated recruitment and a mid-2026 interim analysis.

CurveBeam AI reports a 33% increase in Q1 FY26 purchase orders, secures A$6.5 million in new funding, and finalizes a strategic joint venture for China distribution and manufacturing rights.

NeuroScientific Biopharmaceuticals has secured regulatory approval for initial patient treatments under its Special Access Program for StemSmart™ in Crohn’s disease, alongside key executive appointments and a manufacturing partnership to support upcoming clinical trials.